Diagnostic Imaging

Cardiology Imaging Technologies presents cardiology clinical trial data on EC-G at the American Society of Nuclear Cardiology 2012 Annual Conference

Posted on: September 12th, 2012

CENTENNIAL, Colo., September 11, 2012 – Cell>Point announced today that Cardiovascular Imaging Technologies presented a Phase 1b clinical trial abstract for its cardiology imaging agent, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glocosamine), used to image ischemic patients during rest and exercise stress testing at the American Society of Nuclear Cardiology 2012 Meeting on September 6, 2012. https://www.cellpointweb.com/pdf/press/CellPoint-Press-Release-Sept-11-2012.pdf See the Myocardial Uptake of…

Cell>Point to Present at the 26th Indian Cooperative Oncology Network (ICON) Meeting in Bengaluru, India

Posted on: April 18th, 2012

CENTENNIAL, Colo., March 17, 2012 – Cell>Point today that Company President David Rollo, M.D., Ph.D.,will present at the 26th Indian Oncology Network (ICON) Meeting in Bengaluru, India, On Saturday, March 27, 2012, at 10:45 a.m. local time. The ICON meeting will be held at the Crowne Plaza in Bengaluru.  

Cell>Point Announces Agreement with the FDA on a Special Protocol Assessment for the Phase 3 Technetium-99m-EC-G Lung Cancer Imaging Trial

Posted on: April 18th, 2012

CENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the U.S. Food and Drug Administration (FDA) indicating that agreement has been reached pursuant to a Special Protocol Assessment regarding the design of its Phase 3 pivotal clinical study in lung cancer.  

Cell>Point Executes Asia License with HYUN IMC for Cancer and Heart Disease Diagnostic Imaging Agent, Technetium-99m-EC-G

Posted on: April 18th, 2012

CENTENNIAL, Colo., February 28, 2012 – Cell>Point announced today that it had entered into a licensing agreement for countries of the South Korea, Taiwan, Malaysia, Vietnam, and the Philippines with HYUN IMC Co.,Ltd., headquatered in Seoul, South Korea.  

CENTENNIAL, Colo., January 24, 2012—Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.”

Posted on: April 18th, 2012

Cell>Point announced today that it has entered into a long-term collaboration agreement including product licenses for Brazil with MJM Productos Farmaceuticos e de Radioprotecao Ltda., or “Radiopharmacus.” The agreement leads with Cell>Point’s cancer and cardiology molecular imaging agent—EC-G or, specifically, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine)—but covers the entire portfolio of products being developed by Cell>Point. EC-G has completed a…

CENTENNIAL, Colo., November 23, 2011

Posted on: April 14th, 2012

Cell>Point announced today that the University of Texas M.D. Anderson Cancer Center will present pre-clinical results on Cell>Point’s therapeutic, Platinum-EC-G, for Aggressive type-B Lymphoma at the 53rd American Society of Hematology Annual Meeting December 10-13, 2011

CENTENNIAL, Colo., June 6, 2011—Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G

Posted on: April 14th, 2012

https://www.cellpointweb.com/2011-SNM-Final.pdf

CENTENNIAL, Colo., March 18, 2010—Cell>Point announced today that it was awarded March 15, 2011 the North American SPECT Radiopharmaceuticals Technology Innovation Award by Frost & Sullivan.

Posted on: April 14th, 2012

Cell>Point adds Dr. Wayne Yakes to Board of Advisors – 11/22/2010

Posted on: April 14th, 2012

CENTENNIAL, Colo., November 22, 2010 – Cell>Point is pleased to announce that Dr. Wayne Yakes has joined our Board of Advisors.  Dr. Yakes currently serves as the Director of the Vascular Malformation Center, Interventional Neuroradiology and Interventional Radiology – Swedish Medical Center, Englewood, Colorado.  Dr. Yakes is board certified in Radiology, Interventional Radiology and Neuroradiology…

Cell>Point to present at 52nd American Society of Hematology Annual Meeting December 4-7, 2010.

Posted on: April 14th, 2012

CENTENNIAL, Colo., December 1, 2010 – Dr. Lan V. Pham, Department of Hematophathology, The University of Texas M.D. Anderson Cancer Center, will be presenting the following paper titled “Metabolic Targeted Therapy for Aggressive B-cell Lymphomas: Evaluating Glucose Metabolism and the Potential of 187Rhenium-Ethylenedicysteine – N- AcetylGlucosamine (187Re-EC-G) for Therapy” at the 52nd American Society of Hematology Annual…